Increased Nonvertebral Fracture Risk After Roux-en-Y Bypass

This article originally appeared here.
Share this content:
Increased Nonvertebral Fracture Risk After Roux-en-Y Bypass
Increased Nonvertebral Fracture Risk After Roux-en-Y Bypass

TUESDAY, March 7, 2017 (HealthDay News) -- Roux-en-Y gastric bypass (RYGB) is associated with increased nonvertebral fracture risk compared with adjustable gastric banding (AGB), according to a study published online March 2 in the Journal of Bone and Mineral Research.

Elaine W. Yu, M.D., from Massachusetts General Hospital in Boston, and colleagues compared fracture risk in obese adults after RYGB and AGB procedures using claims data from a U.S. commercial health plan. They examined rates of nonvertebral fractures within a propensity-score matched cohort of 15,032 morbidly obese adults who underwent RYGB or AGB surgery from 2005 to 2013.

During a mean follow-up of 2.3±1.9 years there were 281 nonvertebral fractures. The researchers found that compared with AGB patients, RYGB patients had increased risk of nonvertebral fracture (hazard ratio, 1.43). RYGB patients had increased risk of fracture at the hip and wrist (hazard ratios, 1.54 and 1.45, respectively) in fracture site-specific analyses. The risk of nonvertebral fracture associated with RYGB manifested more than two years after surgery and increased in subsequent years; the highest risk was seen in the fifth year after surgery (hazard ratio, 3.91).

"Fracture risk should be considered in risk:benefit discussions of bariatric surgery, particularly among patients with high baseline risk of osteoporosis who are deciding between RYGB and AGB procedures," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Ocrevus to Treat Severe Form of Multiple Sclerosis

FDA Approves Ocrevus to Treat Severe Form of ...

First drug sanctioned in United States for primary progressive multiple sclerosis

Study Explores Links Between Zika, GBS, Microcephaly in Brazil

Study Explores Links Between Zika, GBS, Microcephaly in ...

Apparent resurgence of Zika virus and GBS early in 2016, but no subsequent increase in microcephaly

Inadvertent HPV Vax Doesn't Up Risk of Poor Pregnancy Outcomes

Inadvertent HPV Vax Doesn't Up Risk of Poor ...

No increased risk of major birth defect, spontaneous abortion, preterm birth, low birth weight, SGA

is free, fast, and customized just for you!

Already a member?

Sign In Now »